Tax Season is Here! Save 15% on H&R Block Online
iconAll times are GMT -4. The time now is 03:22 PM. | Search:

» StockRants Stock Forum » Public Stock Forums » Canadian Stock Picks » Strong Buy: (DND.T) FDA decision on 29 May /Mcap 24 M =1000% Potential !



Reply
 
Thread Tools Search this Thread
Old 01-24-2012, 09:02 AM   Nav to Top  #1
Biohero
Senior Trader
 
Biohero's Avatar
 
Join Date: Jan 2012
Location: Frankfurt
Posts: 275
Favorites: Aapl celg onxx
Rep Power: 110
Reputation: 36
Biohero is on a distinguished road
Default (DND.T) FDA decision on 29 May /Mcap 24 M =1000% Potential !

This REAL Undiscovered stock has MONSTER UPSIDE POTENTIAL and NOW is the perfect time to load up the truck before this Goldmine gets discovered .

This low float stock has already 2 approved Drugs in USA and Canada but the real game changer is nearing approval on 29th may 2012 .

Cipher will move into profitability in 1H 2012 .

Cipher will get $9 M upon approval and 15% royalties from their great partner Ranbaxy .

This low float sleeping Giant will move into double digits once the big boys discover this Goldmine ..


Cipher Pharma (DND.TO)

Market Cap: 24 M
Cash: 10.3 M
Price: $ 0.99

burn-rate: 300k per Q
NO DEBT

Shares Out: 24 M ....(CEO owns 15 M Shares)

LOW FLOAT : 5 Mil



Initiating Coverage of Cipher Pharma (december 2011)

We are initiating coverage of Cipher Pharmaceuticals Inc. (DND.TO, T.DND) with an ‘Outperform’ rating and $2.25 price target, or a market capitalization of $50 million. Cipher currently trades with a market capitalization of only $16 million. We believe the story is largely de-risked and under-appreciated by the Street. Cipher currently has two revenue streams in place with royalties and milestones on sales of Lipofen (CIP-fenofibrate) at Kowa Pharma in the U.S. and the recently launched ConZip (CIP-tramadol-ER) at Vertical Pharma in the U.S. We expect a third royalty and milestone stream from the launch of Durela (CIP-tramadol-ER) at Medical Futures within the next few months.

We have established what we believe to be conservative forecasts for these revenue streams going forward to patent expiration on each product, Lipofen (Q1-2015) and ConZip/Durela (2022). We remind investors that Cipher has little to no ongoing costs associated with either product. Therefore, the best way to value these revenue streams is through the net present value (NYSE:NPV - News) of the cash flows using a 20% discount rate. We believe royalties and milestones on Lipofen are worth approximately $7 million in value. Royalties and milestones on ConZip / Durela are worth another $8 million in value. Finally, we forecast that Cipher will exit 2011 with approximately $9 million in cash and equivalents.



…CIP-Isotretinoin Offers Big Upside…

Based on our model, the stock is currently trading below the net present value of the cash flows from Lipofen and ConZip / Durela, plus the cash on hand. That means investors can purchase the stock today and get the CIP-Isotretinoin product, a potential $200 million opportunity in the U.S., for free. Cipher has licenses the rights to CIP-Isotretinoin to Ranbaxy, a major player in the generic Isotretinoin market with branded Sotret. Sotret posted U.S. sales over $120 million in 2008 prior to the FDA mandating a recall on the product due to quality control / GMP issues at the company’s plant in India. We believe that Cipher’s CIP-Isotretinoin, with its superior absorption and bioavailability characteristics will move into the primary detail position for Ranbaxy’s efforts around Isotretinoin.

Cipher is entitled to receive a mid-teens royalty on sales of CIP-Isotretinoin at Ranbaxy, along with the potential for $19 million in milestones ($9 million upon approval and two $5 million cumulative sales related) with roughly 50% economics to Cipher after it pays the sub-royalty to Galephar.



Cipher becomes a different company with CIP-Isotretinoin on the market in the U.S. By 2016, the royalties on CIP-Isotretinoin alone will account for greater than 80% of the top-line.

We also remind investors that Cipher has filed an application for approval with Health Canada. We estimate the Canadian opportunity with CIP-Isotretinoin is around $10 million, and we expect that Cipher will seek to commercialize the drug on its own through the formation of a small internal sales force of 6 to 8 representatives. We assume Canadian approval in mid-2013.

We have conducted a discounted cash flow (:DCF) analysis to value the shares of Cipher Pharmaceuticals Inc. Above we note that our NPV / Sum-of-Parts analysis for the cash flow from Lipofen and ConZip / Durela alone shows a market value of $23.8 million. However, this is just to give investors a sense of the downside to the Cipher story. At today’s value, the stock is trading on the present value of these cash flows. We see little downside in the stock price as long as Lipofen and ConZip / Durela meet our forecasts.

Upside comes with the approval of CIP-Isotretinoin. Cipher will receive a net $4.5 million cash payment from Ranbaxy if the U.S. FDA approves CIP-Isotretinoin. Our model (posted below) shows that operating cash flow should turn positive immediately after the approval of CIP-Isotretinoin. That means that by the end of 2012, Cipher could be collecting revenues from three approved products in the U.S., with a growing cash balance of over $10 million in the bank, and generating positive cash flow. We think that this presents the clear opportunity to in-licenses yet another 505(b)(2)-like product for late-stage development and commercialization in 2013. We would be buyers of Cipher’s stock today, ahead of what we see as a transformational 2012 coming with the potential approval of CIP-Isotretinoin. Our rating is ‘Outperform’.
Biohero is offline   Rate this post Yes | No Reply With Quote
Reply

Similar Threads
Thread Thread Starter Forum Replies Last Post
Strong Buy: Blockbuster Drug approval in 2H11(Mcap 81 M) =Multibagger Potential biotechmaster US Stock Picks 0 05-23-2011 07:47 AM
Strong Buy: FDA approval within 4 Weeks (Mcap 24 M$) Shares Out 11 M biotechmaster US Stock Picks 4 12-13-2010 07:44 AM
Spec: NGSX - FDA decision date 8/16/09 kabilius US Stock Picks 1 08-05-2009 06:58 PM
Spec: FDA decision dates - Medical Devices kabilius US Stock Picks 0 08-01-2009 01:50 PM
NRIFF (August 5,2009 FDA decision Date) nahoma8 US Stock Picks 20 06-23-2009 11:57 AM


Thread Tools Search this Thread
Search this Thread:

Advanced Search

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is On